# US 2017/0319669 A1 · Method of enhancing viral-mediated gene delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319669 A1
- Document ID: US20170319669A1
- Status: Published application
- Kind: A1
- Application number: 15/586,164
- Filed: 2017-05-03
- Published: 2017-11-09
- Earliest claimed: 2016-05-03
- Applicants: Wayne State University
- Inventors: Zhuo-Hua PAN; Shengjie CUI; Gary ABRAMS
- Web page: https://patentgrep.com/patent/US20170319669A1

## CPC

- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/05: Dipeptides
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/01: DNA viruses
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/0083: {characterised by an aspect of the administration regime}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2799/021: for the expression of a heterologous nucleic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides methods for enhancing the delivery of viral vectors to the eye of a subject by administering a proteasome inhibitor or and a viral vector ending a gene of interest to the eye.

## Claims

### Claim 1

A method of enhancing the delivery of a gene of interest to an eye of a subject comprising administering a proteasome inhibitor and a viral vector encoding the gene of interest to the eye.

### Claim 2 (depends on 1)

The method of claim 1, wherein the proteasome inhibitor is doxorubicin (DOX), aclarubicin, bortezomib, lactacystin, disulfiram epigallocatechin-3-gallate marizomib (salinosporamide A), oprozomib (ONX-0912), delanzomib (CEP-18770) epoxomicin, MG132, beta-hydroxy beta-methylbutyrate or carfilzomib.

### Claim 3 (depends on 1)

The method of claim 1, wherein the gene of interest is an opsin.

### Claim 4 (depends on 3)

The method of claim 3, wherein the opsin is selected from the group consisting of channelrhodopsin, halorhodopsin, melanopsin, pineal opsin, bacteriorhodopsin, and proteorhodopsin, or a functional variant thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the gene of interest is operably linked to a cell-specific promoter.

### Claim 6 (depends on 1)

The method of claim 1, wherein the viral vector is encapsulated in a nanoparticle, a polymer, or a liposome.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is suffering from an ocular disease or disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein the ocular disease is retinoblastoma, ocular melanoma, diabetic retinopathy, hypertensive retinopathy, or an inflammation of ocular tissue.

### Claim 9 (depends on 1)

The method of claim 1, wherein the proteasome inhibitor and the viral vector are delivered concurrently or sequentially.

### Claim 10 (depends on 1)

The method of claim 1, wherein the viral vector is delivered to a retinal cell.

### Claim 11 (depends on 10)

The method of claim 10, wherein the retinal cell is a retinal ganglion cell, a retinal bipolar cell, a retinal horizontal cell, an amacrine cell, a photoreceptor cell, a Müller glial cell, or a retinal pigment epithelial cell.

### Claim 12 (depends on 1, 9)

The method of claim 1 or 9, wherein the proteasome inhibitor and the viral vector are administered to the vitreous of the eye.

### Claim 13 (depends on 1, 9)

The method of claim 1 or 9, wherein the proteasome inhibitor and the viral vector are administered by a route wherein the administration is by injection or infusion.

### Claim 14 (depends on 1, 9)

The method of claim 1 or 9, wherein the proteasome inhibitor and the viral vector are not administered subretinally.

### Claim 15

A method of increasing light sensitivity or improving or restoring vision in a subject comprising administering a proteasome inhibitor and a viral vector that encodes an opsin to the vitreous of the eye.

### Claim 16 (depends on 15)

The method of claim 15, wherein said opsin is selected from the group consisting of channelrhodopsin, halorhodopsin, melanopsin, pineal opsin, bacteriorhodopsin, and proteorhodopsin, or a functional variant thereof.

### Claim 17 (depends on 15)

The method of claim 15, wherein the subject has an ocular disease or disorder.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the ocular disease is retinoblastoma, ocular melanoma, diabetic retinopathy, hypertensive retinopathy, or an inflammation of ocular tissues.
